国家肺癌筛查试验(NLST)中的纵隔淋巴结增大与间期肺癌相关
回顾性分析NLST数据库中26722例参与者,422例(1.6%)在基线低剂量CT筛查中检出≥1.0 cm的非钙化纵隔淋巴结增大。纵隔淋巴结增大与肺癌病例增多(17.1% vs 3.9%,P < .001)、更早诊断、更晚期分期及死亡率增加相关,多数肺癌在基线CT即被检出。
要点
- 基线肺癌筛查CT检出≥1.0 cm非钙化纵隔淋巴结增大的频率为1.6%(422/26722)。
- 纵隔淋巴结增大者肺癌发生率17.1%,无增大者为3.9%,差异有统计学意义(P < .001)。
- 纵隔淋巴结增大与更晚期分期及死亡率增加相关,多数肺癌在基线CT即被检出。
核心结论
- 在低剂量肺癌筛查样本中,非钙化纵隔淋巴结增大与肺癌增多、更早诊断、更晚期病变及死亡率增加相关,作者认为对这些患者采取更积极的治疗似乎是合理的。
研究设计与样本
- 回顾性分析NLST数据库,纳入26722例参与者中基线CT由站点阅片者检出至少一个≥1.0 cm纵隔淋巴结增大的422例(1.6%),每份研究由两名胸部放射科医师独立复核,测量两个最大淋巴结并记录形态学特征;排除纵隔淋巴结广泛钙化或淋巴结小于1 cm的扫描。
关键影像表现/征象
- 纵隔淋巴结增大定义为站点阅片者在基线CT上检出的至少一个≥1.0 cm的纵隔淋巴结。
- 两名胸部放射科医师独立复核并测量两个最大淋巴结,记录形态学特征。
- 纵隔淋巴结增大与肺结节的存在相关(P < .001)。
- 纵隔淋巴结增大与肺癌组织学表现、CT表现或肺结节位置无关联(基于未校正两两关联分析,P > .05)。
诊断标准与关键数值
- 纵隔淋巴结增大标准:基线CT上至少一个≥1.0 cm的纵隔淋巴结(由站点阅片者识别)。
- 纵隔淋巴结增大组肺癌发生率17.1%(72/422,95% CI:13.6,21.0),无增大组3.9%(1017/26300,95% CI:3.6,4.1),P < .001。
- 限制性平均生存时间±标准误:纵隔淋巴结增大组2285天±44 vs 无增大组2611天±2,P < .001。
- 纵隔淋巴结增大组中肺癌在基线筛查CT检出者11.8%(50/422,95% CI:8.9,15.3)vs T1-T7检出者5.3%(22/422,95% CI:3.3,7.8),P < .001。
- 初诊分期:纵隔淋巴结增大且患肺癌者中IIIA期31%(22/72)vs IA期40.3%(410/1017),P < .001。
临床应用与阅片要点
- 作者认为,对基线肺癌筛查CT检出非钙化纵隔淋巴结增大的患者,采取更积极的治疗似乎是合理的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There are currently no evidence-based guidelines for the management of enlarged mediastinal lymph nodes found on lung cancer screening (LCS) CT scans. Purpose To assess the frequency and clinical significance of enlarged mediastinal lymph nodes on the initial LCS CT scans in National Lung Screening Trial (NLST) participants. Materials and Methods A retrospective review of the NLST database identified all CT trial participants with at least one enlarged (≥1.0 cm) mediastinal lymph node identified by site readers on initial CT scans. Each study was reviewed independently by two thoracic radiologists to measure the two largest nodes and to record morphologic characteristics. Scans with extensively calcified mediastinal lymph nodes or nodes measuring less than 1 cm were excluded. Frequency and time to lung cancer diagnosis, lung cancer stage, and histologic findings were compared between NLST participants with and without lymphadenopathy. Results Of the 26 722 NLST participants, 422 (1.6%) had enlarged noncalcified mediastinal lymph nodes on the initial LCS CT scan. Mediastinal lymphadenopathy was associated with an increase in lung cancer cases (72 of 422 participants [17.1%; 95% CI: 13.6, 21.0] vs 1017 of 26 300 [3.9%; 95% CI: 3.6, 4.1]; P < .001), earlier diagnosis (restricted mean survival time ± standard error, 2285 days ± 44 vs 2611 days ± 2; P < .001), the presence of lung nodules (P < .001), advanced stage at presentation (22 of 72 participants [31%] with cancer at stage IIIA vs 410 of 1017 [40.3%] at stage IA; P < .001), and increased mortality (P < .001). The majority of participants with lung cancers in the LCS group with mediastinal lymphadenopathy were detected at initial LCS CT (50 of 422 participants [11.8%; 95% CI: 8.9, 15.3] vs T1-T7, 22 of 422 [5.3%; 95% CI: 3.3, 7.8]; P < .001). There was no association between mediastinal lymphadenopathy and lung cancer histologic findings, CT appearance, or location of lung nodules (P > .05 based on unadjusted pairwise association analyses). Conclusion Noncalcified mediastinal lymphadenopathy in the low-dose lung cancer screening study sample was associated with an increase in lung cancer, an earlier diagnosis, more advanced-stage disease, and increased mortality. More aggressive treatment of these patients appears warranted. © RSNA, 2021 Online supplemental material is available for this article. See also the editorials by McLoud and by Mascalchi and Zompatori in this issue.
引用
- Chalian, McAdams, Lee, et al. Mediastinal Lymphadenopathy in the National Lung Screening Trial (NLST) Is Associated with Interval Lung Cancer. Radiology. 2021. PMID: 34812667. doi:10.1148/radiol.210522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。